Clinical Trial Update: A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors with FGFR2 Alterations [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating KNT-0916 in unresectable or metastatic solid tumors with FGFR2 alterations. The trial status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• KNT-0916

Snippet

Sponsor: KinoTeck Therapeutics Co., Ltd | Conditions: Solid Tumors with FGFR2 Alterations, Adult | Phase 1 | Status: NOT_YET_RECRUITING